• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

还没做过化疗,EGFR是野生型的病友一定要去做ALK的检测

  [复制链接]
160074 161 godblessmymum 发表于 2012-6-16 23:11:32 |
健康活着  小学五年级 发表于 2012-9-18 18:53:34 | 显示全部楼层 来自: 广东广州

* c1 N4 M0 u% U: i- m" @% j( Z) U可以,但要有针对性,
落花无意  小学六年级 发表于 2012-9-22 15:56:39 | 显示全部楼层 来自: 上海
请问,肺鳞癌,只做过一次化疗,骨髓抑制严重,后吃特罗凯4个月基本无效,可以参加实验组吗?
godblessmymum  大学二年级 发表于 2012-9-24 20:13:39 | 显示全部楼层 来自: 上海虹口区
不可以了,要没做过任何治疗的,包括化疗和靶向药
老马  博士一年级 发表于 2012-10-14 22:18:42 | 显示全部楼层 来自: 浙江温州
Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  
0 y3 \! f8 Q* x7 z, V; A
' h0 Y; I& \2 Y& @- _
2 z7 |# D6 x! K" K+ ~0 i% bSub-category:
' k$ [4 o( c1 nMolecular Targets
, A2 I- n' _) Z3 H3 u% X! \% V2 `5 ]* o5 C) R5 _( S

8 b/ R7 {: D7 nCategory:
' V6 V* y/ f9 X+ K7 b2 f2 Q1 kTumor Biology
/ a2 V7 N4 |, j( h5 ?& h
1 @. n2 |2 X; _7 k1 i# A$ T2 d* ?0 g+ f8 W
Meeting:
% Y9 O* m  `0 p1 P  B, l. O" _8 O2011 ASCO Annual Meeting , K0 n6 y, c, I0 {& R/ ~& j

" H7 b6 R7 X2 Y
# s/ ~4 n6 `4 @2 HSession Type and Session Title:
2 |8 i) i' U0 `6 f0 ^0 Y6 u" bPoster Discussion Session, Tumor Biology + {+ u: v9 y  m1 H* {! B, l
  X1 e4 c1 b3 E+ q3 j

9 y7 ~" Z* W" U9 p+ Y: O3 EAbstract No:
( _8 y, j7 ~! p9 f6 a: j10517
9 d4 I, ]; y" z( o! E* w, L8 S  w( T
8 W3 U% n- X% [2 G1 ?5 t* y+ `$ u" m% G! U4 q/ d
Citation:" {( v6 n) j0 O. F7 S7 `
J Clin Oncol 29: 2011 (suppl; abstr 10517) 0 k1 i  \# V6 a* h2 i) ~% R0 H
5 n5 R  K' ^2 M2 c5 h

/ S/ |9 n- U: {( n# R* D/ BAuthor(s):
1 p+ j, u1 F! ^. s7 nJ. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
- J( u1 R! ?& X, w4 W- Z! O: F- K, @$ k" |3 f% x
! |/ ^8 S! }2 @# Y& r$ Q6 Q

& {/ R2 Z# o: {" gAbstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.7 ~- i% p* u& a7 Q  c: D, M

, T4 h: v1 m) N% BAbstract Disclosures9 W8 w4 y# u# ?" ^: w

0 q+ B% v7 _" K3 E/ J; M- RAbstract:/ f, Q+ _& v& a1 D, ^9 a

( x" _7 y, Y$ O7 k5 i6 X. m$ f& m. I* c
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.0 c; g3 _4 i- M

4 Q/ w0 I" d/ e3 Q
6 Y" f# M! a4 K
个人公众号:treeofhope
累计签到:8 天
连续签到:1 天
[LV.3]与爱熟人
一只白杨  大学一年级 发表于 2012-11-15 17:48:59 | 显示全部楼层 来自: 广东广州
由吴一龙教授牵头的A80810029临床试验上周启动,初诊未治疗的晚期肺腺癌患者检测到ALK阳性,可参加一线crizotinib 对比力比泰+卡铂的临床研究,药物全部免费,即使分配到力比泰组,疾病进展之后可免费获得crizotinib.
boeun  小学四年级 发表于 2012-11-18 16:37:21 | 显示全部楼层 来自: 福建泉州
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
godblessmymum  大学二年级 发表于 2012-11-18 23:23:21 | 显示全部楼层 来自: 上海杨浦区
boeun 发表于 2012-11-18 16:37   X& Q" k8 u6 W- x1 Z# T
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
$ o5 q' Z) I- P7 t
化疗过的没机会了
helpU  高中三年级 发表于 2012-12-3 21:04:24 | 显示全部楼层 来自: 北京
平安! 发表于 2012-7-20 11:20
8 h. x$ L. _4 l, \) w2 F5 Q1 U易瑞沙、特罗凯有效的病人基本上可以断定ALK(-)。极其罕见EGFR、ALK同时突变的。% ^5 d, I+ }" Z' }) ~" J
ALK一个指标医院要900多 ...

, S& s! I# S- r平安,真的没有希望吗?我弟弟虽然特罗凯有效,但是EGFR是野生型,不是突变啊。有没有必要去检测ALK呢?- c, @% W6 ?( C# h
; r# Q5 ?4 }6 Y& u) B: ^3 h4 H- w
现在病情进展,快没招儿了。
294170420  初中二年级 发表于 2012-12-4 22:04:38 | 显示全部楼层 来自: 浙江丽水
好像想加入挺困难的
wdc2482  小学六年级 发表于 2012-12-19 18:47:22 | 显示全部楼层 来自: 青海西宁
小地方没条件做啊

举报 使用道具

回复 支持 0 反对 1

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表